Stockscreener 앱 받기
38.96
3.18%
-1.28
시간 외 거래:
38.96
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Wedbush Adjusts Price Target for Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus
PRAX Stock Target Increased by Baird Amid Positive Epilepsy Drug Outlook | PRAX Stock News - GuruFocus
Wedbush Lifts Price Target on Praxis Precision Medicines to $28 From $26, Keeps Underperform Rating - marketscreener.com
PRAX Unveils Progress in DEE Clinical Programs | PRAX Stock News - GuruFocus
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event - The Manila Times
Clinical Trial Success: Praxis's DEE Drug Cuts Seizures by 90%, Eyes $3B Market Opportunity - Stock Titan
Praxis Precision Medicine (PRAX): Buy Rating Reiterated by Needham | PRAX Stock News - GuruFocus
Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024) - Yahoo Finance
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PRAX Stock News - GuruFocus
Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines Awards 3,688 Restricted Stock Units to 5 New Non-Executive Hires - Stock Titan
Praxis Precision Medicines Provides Corporate Update and Reports - GuruFocus
PRAX Revenue Falls Short as Company Focuses on Epilepsy Portfoli - GuruFocus
PRAX Revenue Falls Short as Company Focuses on Epilepsy Portfolio | PRAX Stock News - GuruFocus
Praxis Precision Medicines, Inc. SEC 10-Q Report - TradingView
Praxis Precision Medicines Reports Significant Progress and Upcoming Milestones in Epilepsy Portfolio - Nasdaq
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results - Yahoo Finance
Wells Fargo & Company MN Boosts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts - Benzinga
PRAX: HC Wainwright Reiterates Buy Rating and $105 Price Target | PRAX Stock News - GuruFocus
Praxis Precision Medicines Inc (PRAX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
A closer look at Praxis Precision Medicines Inc (PRAX) is warranted - uspostnews.com
JPMorgan Chase & Co. Has $746,000 Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) vs. Dr. Reddy’s Laboratories (NYSE:RDY) Head to Head Comparison - Defense World
How To Trade (PRAX) - news.stocktradersdaily.com
Financial Review: Praxis Precision Medicines (NASDAQ:PRAX) & ABIVAX Société Anonyme (NASDAQ:ABVX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $31.31 Million Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Contrasting Praxis Precision Medicines (NASDAQ:PRAX) & Generex Biotechnology (OTCMKTS:GNBT) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Alliancebernstein L.P. Buys 60,587 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by American Century Companies Inc. - Defense World
Vanguard Group Inc. Buys 24,645 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Is Praxis Precision Medicines Inc (PRAX) a good investment opportunity? - uspostnews.com
Norges Bank Purchases New Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines to Hold Virtual Investor Event - GlobeNewswire
Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings) - Benzinga
Major Clinical Updates: Praxis Unveils New Data from 3 Rare Epilepsy Programs - Stock Titan
KLP Kapitalforvaltning AS Buys Shares of 2,800 Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Critical Survey: Praxis Precision Medicines (NASDAQ:PRAX) versus Sycamore Entertainment Group (OTCMKTS:SEGI) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Corebridge Financial Inc. - Defense World
PRAX stock touches 52-week low at $30 amid market challenges - Investing.com India
How to Take Advantage of moves in (PRAX) - news.stocktradersdaily.com
Praxis Precision Medicines to Participate in Upcoming April Conferences - The Manila Times
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
CNS Drug Developer Praxis Sets Key Investor Presentations at Needham and Piper Conferences - Stock Titan
Teacher Retirement System of Texas Invests $305,000 in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Swiss National Bank - Defense World
PRAX: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Praxis Precision Medicines to Present Late-Stage Data on CNS Disorders at AAN 2025 Annual Meeting - Nasdaq
0.39%
3.66%
자본화:
|
볼륨(24시간):